Evidence map›Paper›PMID 34168442›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2021

A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design.

Nobuyuki Hizawa, Koichi Fukunaga, Hisatoshi Sugiura, Yasutaka Nakano, Motokazu Kato, Yutaro Sugiyama, Tomohiro Hanazawa, Toshihiko Kaise, Ruth Tal-Singer, Paul W Jones and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Nobuyuki HizawaDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Koichi FukunagaPulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Hisatoshi SugiuraDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0002-4335-7048
Yasutaka NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Shiga, Japan.ORCID 0000-0001-7516-8690
Motokazu KatoRespiratory Institute, Kamei Hospital, Osaka, Japan.ORCID 0000-0003-0411-8703
Yutaro SugiyamaRespiratory Medical Affair and Development, GSK K.K., Tokyo, Japan.
Tomohiro HanazawaRespiratory Medical Affair and Development, GSK K.K., Tokyo, Japan.
Toshihiko KaiseRespiratory Medical Affair and Development, GSK K.K., Tokyo, Japan.ORCID 0000-0001-6059-7900
Ruth Tal-SingerValue Evidence and Outcomes, GSK, Collegeville, PA, USA.ORCID 0000-0002-5275-8062
Paul W JonesGSK, Brentford, Middlesex, UK.ORCID 0000-0001-6087-9182
Neil BarnesGSK, Brentford, Middlesex, UK.ORCID 0000-0001-7981-5197
Chris ComptonGSK, Brentford, Middlesex, UK.
Takeo IshiiRespiratory Medical Affair and Development, GSK K.K., Tokyo, Japan.
GlaxoSmithKline (Japan) · JPGlaxoSmithKline (Netherlands) · NLGlaxoSmithKline (United States) · USKeio University · JPOsaka Hospital · JPQueen Mary University of London · GBShiga University of Medical Science · JPTohoku University · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) are complex and heterogeneous diseases that share clinical characteristics (phenotypes) and molecular mechanisms (endotypes). Whilst physicians make clinical decisions on diagnostic groups, for some such as ACO there is no commonly accepted criteria. An alternative approach is to evaluate phenotypes and endotypes that are considered to respond well to a specific type of treatment ("treatable traits") rather than diagnostic labels. Purpose: The prospective, longitudinal, and observational TRAIT study will evaluate disease characteristics, including both phenotypes and endotypes, in relation to the presentation of obstructive respiratory disease characteristics in patients diagnosed with asthma, COPD, or ACO in Japan, with the aim of further understanding the clinical benefit of a treatable traits-based approach. Patients and Methods: A total of 1500 participants will be enrolled into three cohorts according to their treating physician's diagnosis of asthma, COPD, or ACO at screening. Part 1 of the study will involve cross-sectional phenotyping and endotyping at study enrollment. Part 2 of the study will evaluate the progression of clinical characteristics, biomarker profiles, and treatment over a 3-year follow-up period. The follow-up will involve three annual study visits and three telephone calls scheduled at 6-month intervals. A substudy involving 50 participants from the asthma cohort (in which the ratio will be approximately 1:1 including 25 participants with a smoking history of ≥10 pack-years and 25 participants with no smoking history), 100 participants from the ACO cohort, and 100 participants from the COPD cohort will evaluate disease phenotypes using inspiratory and expiratory computed tomography scans. Conclusion: TRAIT will describe clinical characteristics of patients with obstructive respiratory diseases to better understand potential differences and similarities between clinical diagnoses, which will support the improvement of personalized treatment strategies.

Indexed as

Pulmonary Disease, Chronic ObstructiveCohort StudiesCross-Sectional StudiesHumansJapanPhenotypeProspective StudiesACOasthmabiomarkersCOPDpersonalized medicinetreatable traits

Identifiers

PMID34168442
PMCPMC8219116
OpenAlexW3168321600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.